← All trials
NCT04469686
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jul 14, 2020
- Last posted
- Jul 31, 2020
- Enrollment
- 618
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cristcot LLCLead sponsor
- Cristcot LLCCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.